Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis

Cristina Domínguez-González, Roberto Fernández-Torrón, Ursula Moore, Carlos Pablo de Fuenmayor-Fernández de la Hoz, Beatriz Vélez-Gómez, Juan Antonio Cabezas, Jorge Alonso-Pérez, Laura González-Mera, Montse Olivé, Jorge García-García, Germán Moris, Juan Carlos León Hernández, Nuria Muelas, Emilia Servian-Morilla, Miguel A Martin, Jordi Díaz-Manera, Carmen Paradas, Cristina Domínguez-González, Roberto Fernández-Torrón, Ursula Moore, Carlos Pablo de Fuenmayor-Fernández de la Hoz, Beatriz Vélez-Gómez, Juan Antonio Cabezas, Jorge Alonso-Pérez, Laura González-Mera, Montse Olivé, Jorge García-García, Germán Moris, Juan Carlos León Hernández, Nuria Muelas, Emilia Servian-Morilla, Miguel A Martin, Jordi Díaz-Manera, Carmen Paradas

Abstract

Background and objective: TK2 deficiency (TK2d) is a rare mitochondrial disorder that manifests predominantly as a progressive myopathy with a broad spectrum of severity and age of onset. The rate of progression is variable, and the prognosis is poor due to early and severe respiratory involvement. Early and accurate diagnosis is particularly important since a specific treatment is under development. This study aims to evaluate the diagnostic value of lower limb muscle MRI in adult patients with TK2d.

Methods: We studied a cohort of 45 genetically confirmed patients with mitochondrial myopathy (16 with mutations in TK2, 9 with mutations in other nuclear genes involved in mitochondrial DNA [mtDNA] synthesis or maintenance, 10 with single mtDNA deletions, and 10 with point mtDNA mutations) to analyze the imaging pattern of fat replacement in lower limb muscles. We compared the identified pattern in patients with TK2d with the MRI pattern of other non-mitochondrial genetic myopathies that share similar clinical characteristics.

Results: We found a consistent lower limb muscle MRI pattern in patients with TK2d characterized by involvement of the gluteus maximus, gastrocnemius medialis, and sartorius muscles. The identified pattern in TK2 patients differs from the known radiological involvement of other resembling muscle dystrophies that share clinical features.

Conclusions: By analyzing the largest cohort of muscle MRI from patients with mitochondrial myopathies studied to date, we identified a characteristic and specific radiological pattern of muscle involvement in patients with TK2d that could be useful to speed up its diagnosis.

Keywords: MRI; Mitochondrial myopathy; TK2.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any conflict of interest.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Heatmap of muscles of the lower limbs in patients with mitochondrial myopathies, disease duration, and MRC scale. A Heatmap showing involvement of pelvic, thigh and leg muscles. Patients and muscles are ordered according to hierarchical clustering with increasing grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle in a patient is indicated by the color of the square. Grey squares mean that data are not available. The column in the top left contains information related to the genetic data of the patient (legend in the bottom left). We have also included a column with information about the muscle strength of the patients measured using the MRC scale in red and a column to the far right with information about the disease duration (time from onset of symptom to the MRI in years). B Heatmaps showing the median Mercuri score of the muscles of the pelvis, thigh and leg areas. The three group of diseases and muscles are ordered according to hierarchical clustering. The column in the top right contains information related to the genetic data of the patient (legend in the bottom left). Group 1: mtDNA single large-scale deletion; Group 2: Point mtDNA mutation (MTCO1, MTTL1, MTTK, MTTS1, and MTTN genes); Group 3: Mutation in nuclear genes involved in mtDNA maintenance (POLG, TWNK, RRM2B and TK2 genes). No pattern of muscle involvement was identified in any group
Fig. 2
Fig. 2
Heatmap of muscles of the lower limbs in patients with TK2 gene mutations, disease duration, and MRC scale. Heatmap showing involvement of pelvic, thigh, and leg muscles in patients with mutations in the TK2 gene. Patients and muscles are ordered according to hierarchical clustering with increasing grading in fat replacement severity from the bottom to the top (patients—rows) and from the left to the right (muscles—columns). The score of a muscle in a patient is indicated by the color of the square. Grey squares mean that data are not available. The column in the top left contains information related to disease duration (time from onset of symptom to the MRI in years) and the column in the top right provides information about muscle strength of the patients measured using the MRC scale in red. Legends can be found at the bottom on the right
Fig. 3
Fig. 3
Muscle MRI pattern of the lower limbs in TK2d patients compared to other myopathies. A Muscle MRI from three TK2d patients with different disease duration and weakness severity showed that the most affected muscles were the gluteus maximus (arrows), the sartorius (arrowheads), and the gastrocnemius medialis muscles (asterisks). B Muscle MRI from patients with other mitochondrial myopathies as the one linked to point mutation in the mitochondrial gene MTTN, or other myopathies with similar clinical characteristics as FSHD or OPMD, showed a very different pattern of muscle involvement, highlighting the full preservation of the sartorius muscles (open arrows), even when other muscles are severely degenerated
Fig. 4
Fig. 4
Boxplots showing values of the Mercuri score of muscles of the pelvis, thigh and leg of TK2d, other mitochondrial myopathies, FSHD and OPMD patients. Value of the Kruskal–Wallis test is shown per every comparison and when significant, Wilcoxon test is applied to compare TK2 and the other three diseases
Fig. 5
Fig. 5
PCA analysis. TK2d compared to other mitochondrial myopathies (A) showed that gluteus maximus, vastus lateralis, obturator externus, sartorius, and flexor digitorum were the muscles that differentiated most one disease to another. B TK2d compared to FSHD showed that gluteus maximus, obturator externus, sartorius, the short head of biceps femoris, semimembranosus, flexor digitorum, extensor digitorum, and tibialis anterior were the muscles that differentiated most one disease to another. C TK2d compared to OPMD showed that gluteus maximus, vastus lateralis, obturator externus, sartorius, and flexor digitorum were the muscles that differentiated most from one disease to another
Fig. 6
Fig. 6
Boxplots showing the difference in Mercuri score between right and left sides of muscles of the pelvis, thigh and leg of FSHD and TK2d. Results of the Wilcoxon test applied to identify significant differences are shown

References

    1. Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet. 2001;29(3):342–344. doi: 10.1038/ng751.
    1. Béhin A, et al. Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum. Neurology. 2012;78(9):644–648. doi: 10.1212/WNL.0b013e318248df2b.
    1. Domínguez-González C, et al. Late-onset thymidine kinase 2 deficiency: a review of 18 cases. Orphanet J Rare Dis. 2019;14(1):100. doi: 10.1186/s13023-019-1071-z.
    1. Chanprasert S, et al. Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene. Mol Genet Metab. 2013;110(1–2):153–161. doi: 10.1016/j.ymgme.2013.07.009.
    1. Saada A, Ben-Shalom E, Zyslin R, Miller C, Mandel H, Elpeleg O. Mitochondrial deoxyribonucleoside triphosphate pools in thymidine kinase 2 deficiency. Biochem Biophys Res Commun. 2003;310(3):963–966. doi: 10.1016/j.bbrc.2003.09.104.
    1. Ashley N, et al. Defects in maintenance of mitochondrial DNA are associated with intramitochondrial nucleotide imbalances. Hum Mol Genet. 2007;16(12):1400–1411. doi: 10.1093/hmg/ddm090.
    1. Garone C, et al. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018 doi: 10.1136/jmedgenet-2017-105012.
    1. Wang J, et al. Clinical and molecular spectrum of thymidine kinase 2-related mtDNA maintenance defect. Mol Genet Metab. 2018 doi: 10.1016/j.ymgme.2018.04.012.
    1. Rodríguez-López C, et al. Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. J Med Genet. 2020 doi: 10.1136/jmedgenet-2019-106649.
    1. Domínguez-González C, et al. Deoxynucleoside therapy for thymidine kinase 2-deficient myopathy. Ann Neurol. 2019;86(2):293–303. doi: 10.1002/ana.25506.
    1. Mancuso M, McFarland R, Klopstock T, Hirano M, et al. International Workshop: outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16–18 November 2016, Rome, Italy. Neuromuscul Disord. 2017;27(12):1126–1137. doi: 10.1016/j.nmd.2017.08.006.
    1. Fischer D, et al. Distinct muscle imaging patterns in myofibrillar myopathies. Neurology. 2008;71(10):758–765. doi: 10.1212/01.wnl.0000324927.28817.9b.
    1. Tasca G, et al. Different molecular signatures in magnetic resonance imaging-staged facioscapulohumeral muscular dystrophy muscles. PLoS ONE. 2012;7(6):e38779. doi: 10.1371/journal.pone.0038779.
    1. Alonso-Jimenez A, et al. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. J Neurol Neurosurg Psychiatry. 2019;90(5):576–585. doi: 10.1136/jnnp-2018-319578.
    1. Cohen BH. Mitochondrial and metabolic myopathies. Continuum. 2019;25(6):1732–1766. doi: 10.1212/CON.0000000000000805.
    1. Gorman GS, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016;2:16080. doi: 10.1038/nrdp.2016.80.
    1. Dominguez-Gonzalez C, et al. Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy. Sci Rep. 2020;10(1):10111. doi: 10.1038/s41598-020-66940-8.
    1. Paradas C, Gutiérrez Ríos P, Rivas E, Carbonell P, Hirano M, DiMauro S. TK2 mutation presenting as indolent myopathy. Neurology. 2013;80(5):504–506. doi: 10.1212/WNL.0b013e31827f0ff7.
    1. Hankiewicz K, et al. Whole-body muscle magnetic resonance imaging in SEPN1-related myopathy shows a homogeneous and recognizable pattern. Muscle Nerve. 2015;52(5):728–735. doi: 10.1002/mus.24634.
    1. Tordjman M, et al. Muscular MRI-based algorithm to differentiate inherited myopathies presenting with spinal rigidity. Eur Radiol. 2018 doi: 10.1007/s00330-018-5472-5.
    1. Peterle E, Fanin M, Semplicini C, Padilla JJ, Nigro V, Angelini C. Clinical phenotype, muscle MRI and muscle pathology of LGMD1F. J Neurol. 2013;260(8):2033–2041. doi: 10.1007/s00415-013-6931-1.
    1. Carbonell-Corvillo P, et al. A novel MYH7 founder mutation causing Laing distal myopathy in Southern Spain. Neuromuscul Disord. 2018 doi: 10.1016/j.nmd.2018.07.006.
    1. Castiglioni C, et al. Muscle magnetic resonance imaging and histopathology in ACTA1-related congenital nemaline myopathy. Muscle Nerve. 2014;50(6):1011–1016. doi: 10.1002/mus.24353.
    1. Olivé M, et al. Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul Disord. 2011;21(8):533–542. doi: 10.1016/j.nmd.2011.05.002.
    1. Leung DG. Magnetic resonance imaging patterns of muscle involvement in genetic muscle diseases: a systematic review. J Neurol. 2017;264(7):1320–1333. doi: 10.1007/s00415-016-8350-6.
    1. Aivazoglou LU, et al. MR imaging of inherited myopathies: a review and proposal of imaging algorithms. Eur Radiol. 2021 doi: 10.1007/s00330-021-07931-9.
    1. Verdú-Díaz J, et al. Accuracy of a machine learning muscle MRI-based tool for the diagnosis of muscular dystrophies. Neurology. 2020;94(10):e1094–e1102. doi: 10.1212/WNL.0000000000009068.
    1. Diaz-Manera J, et al. Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials. J Neurol Neurosurg Psychiatry. 2018;89(10):1071–1081. doi: 10.1136/jnnp-2017-317488.
    1. Alonso-Pérez J, et al. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain. 2020;143(9):2696–2708. doi: 10.1093/brain/awaa228.
    1. Tasca G, Monforte M, Nesti C, Santorelli FM, Silvestri G, Ricci E. Concentric muscle involvement in POLG-related distal myopathy. Neuromuscul Disord. 2017;27(5):500–501. doi: 10.1016/j.nmd.2017.03.001.
    1. Donkervoort S, et al. MSTO1 mutations cause mtDNA depletion, manifesting as muscular dystrophy with cerebellar involvement. Acta Neuropathol. 2019;138(6):1013–1031. doi: 10.1007/s00401-019-02059-z.
    1. Hedermann G, et al. Progressive fat replacement of muscle contributes to the disease mechanism of patients with single, large-scale deletions of mitochondrial DNA. Neuromuscul Disord. 2018;28(5):408–413. doi: 10.1016/j.nmd.2018.02.008.
    1. Matthews PM, et al. In vivo magnetic resonance spectroscopy of brain and muscle in a type of mitochondrial encephalomyopathy (MERRF) Ann Neurol. 1991;29(4):435–438. doi: 10.1002/ana.410290416.
    1. Matthews PM, Allaire C, Shoubridge EA, Karpati G, Carpenter S, Arnold DL. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology. 1991;41(1):114–120. doi: 10.1212/wnl.41.1.114.
    1. Kemp GJ, Ahmad RE, Nicolay K, Prompers JJ. Quantification of skeletal muscle mitochondrial function by 31P magnetic resonance spectroscopy techniques: a quantitative review. Acta Physiol. 2015;213(1):107–144. doi: 10.1111/apha.12307.
    1. Kornblum C, et al. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur J Neurol. 2005;12(4):300–309. doi: 10.1111/j.1468-1331.2004.00970.x.
    1. Parikh S, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2017;19(12):12. doi: 10.1038/gim.2017.107.

Source: PubMed

3
Abonner